Back to news

SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering

Globe Newswire•18/11/2026•21:59 ET
0

Key Highlights

  • ➤SELLAS (SLS) priced 11,538,462 shares at $13.00 each
  • ➤Gross proceeds expected to reach $150.0 million before offering expenses
  • ➤Underwriters received a 30-day option for 1,730,769 additional shares
  • ➤Offering expected to close November 20, 2026, subject to customary conditions

NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $150.0 million before deducting underwriting discounts and commissions and offering expenses. In addition, SELLAS has also granted the underwriters a 30-day option to purchase up to 1,730,769 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 20, 2026, subject to the satisfaction of customary closing conditions.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in